Review
Endocrinology & Metabolism
Aya Bassatne, Abir Bou Khalil, Marlene Chakhtoura, Asma Arabi, Catherine Van Poznak, Ghada El-Hajj Fuleihan
Summary: This study suggests a protective effect of antiresorptive drugs on bone mineral density and bone turnover markers in postmenopausal women with non-metastatic breast cancer on aromatase inhibitors (AIs), but the data on fracture risk reduction is still unclear.
METABOLISM-CLINICAL AND EXPERIMENTAL
(2022)
Article
Multidisciplinary Sciences
Kaiyue Wang, Lu Shen, Wei Tian, Suzhan Zhang
Summary: This retrospective cohort study aimed to investigate the effect of endocrine therapy on serum lipids in premenopausal women with early breast cancer. The results showed that different types of endocrine treatments had varying effects on blood lipids, with some treatments improving lipid levels but also carrying certain risks.
SCIENTIFIC REPORTS
(2022)
Article
Medicine, General & Internal
Hikmat Abdel-Razeq, Ula Al-Rasheed, Noor Mashhadani, Akram Al-Ibraheem, Rashid Abdel-Razeq, Shereen Abu Jaradeh, Razan Mansour, Rayan Bater, Shrouq Tbayshat
Summary: This study suggests that implementing a comprehensive bone health program can maintain or improve bone mineral density in postmenopausal patients with early-stage breast cancer treated with aromatase inhibitors.
IRISH JOURNAL OF MEDICAL SCIENCE
(2022)
Article
Oncology
Miryam Yusufov, Margo Nathan, Aleta Wiley, Julia Russell, Ann Partridge, Hadine Joffe
Summary: Pre-existing psychological and menopause symptoms can predict non-adherence to oral anti-estrogen therapies in early-stage hormone receptor-positive breast cancer. These symptoms can help identify patients at risk for non-adherence and guide interventions for psychological and symptom management.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Article
Oncology
Leonor Vasconcelos de Matos, Leonor Fernandes, Maria Teresa Neves, Fatima Alves, Mafalda Baleiras, Andre Ferreira, Pedro Giesteira Cotovio, Tiago Dias Domingues, Mariana Malheiro, Ana Placido, Maria Helena Miranda, Ana Martins
Summary: This study evaluated bone loss, fracture incidence, and risk factors in post-menopausal women receiving AI therapy for HR+ EBC. Age and time under AI were identified as independent predictors of fracture, with fractures associated with lower disease-free survival.
Article
Multidisciplinary Sciences
Eun Heui Kim, Yun Kyung Jeon, Kyoungjune Pak, Taewoo Kang, Kyung-Eun Kim, Seong-Jang Kim, In-Joo Kim, Keunyoung Kim
Summary: This study compared the changes in lumbar spine and femur BMD and TBS in breast cancer patients undergoing TMXF or TMXF combined with GnRH analog therapy. TBS was found to be more sensitive in reflecting bone microarchitectural changes caused by hormone therapies compared to BMD.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Lindsay J. Collin, Deirdre P. Cronin-Fenton, Thomas P. Ahern, Michael Goodman, Lauren E. McCullough, Lance A. Waller, Anders Kjaersgaard, Per Damkier, Peer M. Christiansen, Bent Ejlertsen, Maj-Britt Jensen, Henrik Toft Sorensen, Timothy L. Lash
Summary: This study evaluated the association between early discontinuation of endocrine therapy and breast cancer recurrence in premenopausal women. The results showed a higher rate of recurrence in women who discontinued endocrine therapy compared to those who completed the recommended treatment. These findings emphasize the importance of clinical follow-up and behavioral interventions to support the persistence of adjuvant endocrine therapy in preventing breast cancer recurrence.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Raffaella D'Onofrio, Claudia Omarini, Angela Toss, Isabella Sperduti, Federico Piacentini, Monica Barbolini, Laura Cortesi, Elena Barbieri, Elisa Pettorelli, Chiara Chiavelli, Massimo Dominici, Luca Moscetti
Summary: In premenopausal HR + EBC patients, those who received AI/OFS treatment had lower recurrence rate and higher disease-free survival compared to those who received T/OFS treatment. Patients who completed 5-year hormone therapy had significantly higher disease-free survival than those who stopped before 5 years. However, there were adverse events and early discontinuation issues during treatment.
CLINICAL BREAST CANCER
(2023)
Article
Pharmacology & Pharmacy
Chanhyun Park, Ji-Haeng Heo, Sanica Mehta, Sola Han, Jennifer C. Spencer
Summary: This study aimed to estimate the impact of individual adjuvant endocrine therapy (AET) types on treatment efficacy and overall survival in breast cancer patients. The study found that the tamoxifen group had a faster decrease in adherence compared to anastrozole, letrozole, and exemestane, and higher adherence was associated with a lower risk of mortality.
CLINICAL DRUG INVESTIGATION
(2023)
Article
Oncology
Rebecca Pedersini, Pierluigi di Mauro, Vito Amoroso, Vincenza Castronovo, Manuel Zamparini, Sara Monteverdi, Lara Laini, Greta Schivardi, Deborah Cosentini, Salvatore Grisanti, Sara Marelli, Luigi Ferini Strambi, Alfredo Berruti
Summary: The use of aromatase inhibitors (AIs) as adjuvant therapy for early breast cancer does not affect insomnia, anxiety, or depression. However, it significantly decreases quality of life and increases the frequency and severity of restless legs syndrome (RLS). Patients with RLS may benefit from additional psychological support.
Article
Oncology
Tao Wang, Yu-Yan Huang, Xian-Liang Liu, Alex Molassiotis, Li-Qun Yao, Si-Lin Zheng, Jing-Yu (Benjamin) Tan, Hou-Qiang Huang
Summary: This cross-sectional study in China focused on joint pain in breast cancer survivors receiving AI treatment. The study found that Chinese breast cancer survivors commonly experience joint pain, particularly in the knees. Factors such as poorer physical well-being/functioning, previous use of AI treatment, presence of osteoarthritis, and receiving physiotherapy were identified as correlates of greater severity of pain and pain interference.
SUPPORTIVE CARE IN CANCER
(2022)
Review
Chemistry, Medicinal
Ankita Sood, Damanpreet Kaur Lang, Rajwinder Kaur, Balraj Saini, Sandeep Arora
Summary: Treatment for breast cancer remains challenging, with aromatase inhibitors showing significantly improved efficacy and safety compared to other drugs.
CURRENT TOPICS IN MEDICINAL CHEMISTRY
(2021)
Article
Endocrinology & Metabolism
Gherardo Mazziotti, Rebecca Pedersini, Walter Vena, Deborah Cosentini, Flaminia Carrone, Stella Pigni, Edda L. Simoncini, Rosalba Torrisi, Alberto Zambelli, Davide Farina, Luca Balzarini, Andrea G. Lania, Alfredo Berruti
Summary: This prospective study aimed to investigate the real-life effectiveness of bone-active drugs on the risk of vertebral fractures induced by aromatase inhibitors (AIs) in breast cancer patients. The results suggest that in real-world clinical practice, denosumab and zoledronate can significantly reduce the risk of vertebral fractures in breast cancer patients using AIs.
CALCIFIED TISSUE INTERNATIONAL
(2022)
Article
Oncology
Heather Greenlee, Carlos Iribarren, Jamal S. Rana, Richard Cheng, Mai Nguyen-Huynh, Eileen Rillamas-Sun, Zaixing Shi, Cecile A. Laurent, Valerie S. Lee, Janise M. Roh, Margarita Santiago-Torres, Hanjie Shen, Dawn L. Hershman, Lawrence H. Kushi, Romain Neugebauer, Marilyn L. Kwan
Summary: This study found that women with breast cancer had significantly increased incidence of cardiovascular disease events, CVD-related mortality, and all-cause mortality compared with women without breast cancer, with risks varying according to the history of cancer treatment received. Studies are needed to determine optimal care for women who have received breast cancer treatment to improve cardiovascular outcomes.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Medicine, General & Internal
Milana A. Bergamino, Elena Lopez-Knowles, Gabriele Morani, Holly Tovey, Lucy Kilburn, Eugene F. Schuster, Anastasia Alataki, Margaret Hills, Hui Xiao, Chris Holcombe, Anthony Skene, John F. Robertson, Ian E. Smith, Judith M. Bliss, Mitch Dowsett, Maggie C. U. Cheang
Summary: This study aimed to identify biomarkers for the response of ER+/HER2+ breast cancers to AI treatment. The results showed that HER2-E is a standardized biomarker associated with poor response to AI and worse prognosis in ER+/HER2+ breast cancers. HRD, TP53 mutational score, and immune-tumor tolerance are predictive biomarkers for poor response to AI. Additionally, new molecular subtypes identify non-HER2-E tumors that do not respond to AI and have an increased risk of relapse.